SEC Form 4 · accession 0001209191-17-039824
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Weiser
Director
Period of report
Jun 12, 2017
Accepted (ET)
Jun 14, 2017 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2017 | M | 15,000 | $4.85 | A | 218,670 | D | |
| Common StockF1 | Jun 12, 2017 | F | 13,300 | $5.47 | D | 205,370 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $4.85 | Jun 12, 2017 | M | 15,000 | D | — | Jun 18, 2017 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1Represents shares withheld to pay exercise price.
- F25,000 shares vested and became exercisable on each of 6/18/08, 6/18/09 and 6/18/10.